Key Highlights
- Revenue increased USD 6.3 million, or 8%, to USD 90.4 million from USD 84.1 million a year earlier.
- Anatomic pathology Revenue increased USD 14.9 million, including USD 21.8 million from Assets and Business acquired in the Bako Acquisition.
- Precision diagnostics revenue decreased USD 8.9 million, and BioPharma services revenue increased USD 0.3 million.
- Nine-month revenue increased 3% to USD 246.9 million from USD 239.3 million in the prior-year period.
Fulgent Genetics, Inc. (NASDAQ:FLGT) reported third quarter 2026 revenue of USD 90.4 million, an increase of USD 6.3 million, or 8%, from USD 84.1 million. EPS was negative USD 0.09.
The Quarterly Report states that the Bako Acquisition closed late in the first quarter, so results for the nine months ended September 30, 2026 include only approximately six and a half months of acquired operations.
Revenue by Service Line
The quarterly increase was driven by increases of USD 14.9 million in anatomic pathology and USD 0.3 million in BioPharma services, partially offset by a decrease of USD 8.9 million in precision diagnostics. For nine months, revenue increased USD 7.6 million, or 3%, driven by increases of USD 24.1 million in anatomic pathology and USD 2.3 million in BioPharma services, partially offset by a decrease of USD 18.7 million in precision diagnostics.
The anatomic pathology increase was primarily due to USD 21.8 million and USD 41.3 million of revenue in the three and nine months, respectively, from assets and the business acquired in the Bako Acquisition. This was partially offset by the impact of the final phase of the transition of the billing and revenue cycle management system, which resulted in significant processing backlogs and collections delays.
Anatomic pathology testing Volume can fluctuate during holiday periods and can decline due to extreme adverse weather conditions leading to temporary laboratory closures, as experienced during 2026.
Customers and Growth Factors
For the laboratory services segment, aggregating customers under common control, no customer represented a significant concentration of revenue in the three and nine months ended September 30, 2026. One customer contributed USD 19.2 million, or 23%, of revenue in the three months ended September 30, 2025, and USD 54.4 million, or 23%, in the nine months ended September 30, 2025.
As previously disclosed, the company states that revenues from this customer continue to decline in 2026 as the customer transitions the performance of tests internally.
The company identified four factors affecting growth of these revenue streams: the average price point offered and the insurance payor reimbursement rate, the concentration of its payor base, its Competitive Advantage from a broad and flexible test menu, detection rate and turnaround times, and growth in the size of the addressable market.
Other Revenue Sources
Revenue from sources outside the United States increased USD 0.7 million, or 11%, from USD 6.5 million to USD 7.2 million in the three months ended September 30, 2026, primarily due to increases in total revenue from China of USD 0.3 million and the United Kingdom of USD 0.2 million. Reported detail: Precision diagnostics revenue decreased USD 8.9 million, and BioPharma services revenue increased USD 0.3 million.






Please wait processing your request...